Glucocorticosteroid-free versus glucocorticosteroid-containing immunosuppression for liver transplanted patients

Cochrane Database of Systematic Reviews

Volumn 2015, Issue 12, 2015, Pages

  Fairfield, Cameron ^a   Penninga, Luit ^b   Powell, James ^a   Harrison, Ewen M ^c   Wigmore, Stephen J ^a  

^a ROYAL INFIRMARY OF EDINBURGH   (United Kingdom)

^b University of Copenhagen   (Denmark)

^c UNIVERSITY OF EDINBURGH   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CREATININE; GLUCOCORTICOID; CALCINEURIN INHIBITOR; IMMUNOSUPPRESSIVE AGENT;

ACUTE GRAFT REJECTION; CREATININE BLOOD LEVEL; CYTOMEGALOVIRUS INFECTION; DEATH; DIABETES MELLITUS; DRUG EFFICACY; DRUG SAFETY; DRUG USE; DRUG WITHDRAWAL; END STAGE LIVER DISEASE; GRAFT FAILURE; HEPATITIS C; HUMAN; HYPERCHOLESTEROLEMIA; HYPERLIPIDEMIA; HYPERTENSION; IMMUNOSUPPRESSIVE TREATMENT; INFECTION; INTERMETHOD COMPARISON; INTRAOPERATIVE PERIOD; KIDNEY FAILURE; LIVER TRANSPLANTATION; MALIGNANT NEOPLASM; MORTALITY; POSTOPERATIVE PERIOD; POSTTRANSPLANT LYMPHOPROLIFERATIVE DISEASE; PRIORITY JOURNAL; REVIEW; SYSTEMATIC REVIEW; TREATMENT DURATION; ACUTE DISEASE; ADULT; CHRONIC DISEASE; GRAFT REJECTION; META ANALYSIS; PROCEDURES; RANDOMIZED CONTROLLED TRIAL (TOPIC); RENAL INSUFFICIENCY; TREATMENT WITHDRAWAL;

ACUTE DISEASE; ADULT; CALCINEURIN INHIBITORS; CHRONIC DISEASE; DIABETES MELLITUS; GLUCOCORTICOIDS; GRAFT REJECTION; HUMANS; IMMUNOSUPPRESSION; IMMUNOSUPPRESSIVE AGENTS; LIVER TRANSPLANTATION; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RENAL INSUFFICIENCY; WITHHOLDING TREATMENT;

EID: 84965190365     PISSN: 14651858     EISSN: None     Source Type: Journal    
DOI: 10.1002/14651858.CD007606.pub3     Document Type: Review

References (210)

1. Belli LS, Alberti AB, Vangeli M, Airoldi A, Pinzello G. Tapering offsteroids three months after liver transplantation is not detrimental for hepatitis C virus disease recurrence. Liver Transplantation 2003;9(2):201-2. [DOI: 10.1053/jlts.2002.50033]
2. Belli LS, De Carlis L, Rondinara GF, Romani F, Alberti A, Pirotta V, et al. Prospective randomized trial of steroid withdrawal in liver transplant patients: preliminary report. Transplant International 1994;7(Suppl 1):S88-90.
3. Belli LS, de Carlis L, Rondinara G, Alberti AB, Bellati G, de Gasperi A, et al. Early cyclosporine monotherapy in liver transplantation: a 5-year follow-up of a prospective, randomized trial. Hepatology 1998;27(6):1524-9. [DOI: 10.1002/hep.510270609]
4. De Carlis L, Belli LS, Colella G, Rondinara GF, Slim AO, Alberti A, et al. Serum lipid changes in liver transplantation: effect of steroids withdrawn in a prospective randomized trial under cyclosporine A therapy. Transplantation Proceedings 1999;31(1-2):391-3. [10.1016/S0041-1345(98)01675-3]
5. De Carlis L, Belli LS, Rondinara GF, Alberti A, Sansalone CV, Colella G, et al. Early steroid withdrawal in liver transplant patients: final report of a prospective randomized trial. Transplantation Proceedings 1997;29(1-2):539-42. [DOI: 10.1016/S0041-1345(96)00255-2]
6. Romani F, Belli LS, De Carlis L, Rondinara GF, Alberti A, Sansalone CV, et al. Cyclosporin monotherapy (after 3 months) in liver transplant patients: a prospective randomized trial. Transplantation Proceedings 1994;26(5):2683-5.
7. Belli L, Alberti A, Airoldi A, Cernuschi A, Rondinara G, De Carlis L. Early ribavirin treatment and avoidance of steroids in HCV positive liver transplant candidates: preliminary report of a prospective randomized trial [abstract]. Journal of Hepatology 2000;32(Suppl 2):44. [DOI: 10.1016/S0168-8278(00)80501-2]
8. Belli LS, Alberti AB, Rondinara GF, de Carlis L, Corti A, Mazza E, et al. Early ribavirin treatment and avoidance of corticosteroids in hepatitis C virus (HCV)-positive liver transplant recipients: interim report of a prospective randomized trial. Transplantation Proceedings 2001;33(1-2):1353-4. [10.1016/S0041-1345(00)02507-0]
9. Chen Z-S, He F, Zeng F-J, Jiang J-P, Du D-F, Liu B. Early steroid withdrawal after liver transplantation for hepatocellular carcinoma. World Journal of Gastroenterology 2007;13(39):5273-6.
10. Hu AB, He XS, Wu ZP, Zhu XF, Ma Y, Wang DP, et al. Evaluation of efficacy and safety on steroid withdraw at the seventh day after liver transplantation. Zhonghua Wai Ke Za Zhi 2008;46(15):1126-8.
11. Ju WQ, Guo ZY, Ling X, He XS, Wu LW, Tai Q, et al. Twenty-four hour steroid avoidance immunosuppressive regimen in liver transplant recipients. Experimental and Clinical Transplantation 2012;10(3):258-62.
12. Ju WQ, He XS, Tan YL, Wu LW, Tai Q, Hu AB, et al. Two-dose steroid combined with two-dose daclizumab and tacrolimus regimen in liver transplant recipients. Zhonghua Wai Ke Za Zhi 2009;47(14):1064-6.
13. Wu LW, Guo ZY, Tai Q, Ju WQ, Wang DP, Hu AB, et al. Steroid elimination within 24 hours after orthotopic liver transplantation: effectiveness and tolerability. Hepatobiliary & Pancreatic Diseases International 2012;11(2):137-42.
14. Bonaccorsi-Riani E, Sempoux C, Piette N, Julliard O, Kabamba B, Ciccarelli O, et al. Impact of steroid-avoidance immunosuppression on long-term outcome after liver transplantation for HCV cirrhosis: the need for well documented long-term follow-up. Acta Gastroenterologica Belgica 2012;75(4):411-8.
15. Lerut J, Ciccarelli O, Bonaccorsi-Riani E, Mathis J, Verbaandert C, Talpe S, et al. Tacrolimus (tac) monotherapy in liver transplantation (lt): one-year results of a prospective, randomized, double-blinded placebo-controlled study. Transplantation International 2009;22:84.
16. Lerut J, Mathys J, Lemaire J, Thuyne V, Talpe S, Sempoux C. Tacrolimus monotherapy (TAC-mono) in 100 adult liver transplant (LT) recipients: one year results of a prospective, randomised, blinded, placebo-controlled, single centre study. Transplantation 2004;78(2):173.
17. Lerut J, Mathys J, Lemaire J, Thuyne V, Talpe S, Verbaandert C, et al. Tacrolimus monotherapy (tac-mono) in 100 adult liver transplant (lt) recipients: one year results of a prospective, randomized, blinded, placebo-controlled, investigator driven, single centre study [abstract]. 3rd International Congress on Immunosuppression. San Diego, 2004.
18. Lerut J, Mathys J, Lemaire J, Van Thuyne V, Talpe S, Sempoux C, et al. Tacrolimus monotherapy(TAC-MONO)in 100 adult liver transplant (LT) recipients: one year results of a prospective, randomized, blinded, placebo-controlled, investigated driven, single centre study. Liver Transplantation 2005;11(7):C24.
19. Lerut J, Mathys J, Verbaandert C, Ciecarelli O, Lemaire J, Hetsch N, et al. Tacrolimus monotherapy (TAC-MONO) in 156 primary adult liver transplant (LT) recipients: results of a prospective, randomized, placebo-controlled study. American Journal of Transplantation 2007;7:470.
20. Lerut J, Mathys J, Verbaandert C, Lemaire J, Hetsch N, Ciccarelli O, et al. Tacrolimus monotherapy (TAC-MONO) in adult liver transplantation (LT): results of a prospective, randomized, placebo-controlled blinded study. Transplantation International 2007;20:31.
21. Lerut J, Mathys J, Verbaandert C, Talpe S, Ciccarelli O, Lemaire J, et al. Tacrolimus monotherapy in liver transplantation: one-year results of a prospective, randomized, double-blind, placebo-controlled study. Annals of Surgery 2008;248(6):956-67. [DOI: 10.1097/SLA.0b013e31819009c9]
22. Pinheiro RS, Lai Q, Juri JMR, Santa EC, Ciccarelli O, D'Albuquerque LAC, et al. Is steroid (almost) free immunosuppression a safe approach in adult liver transplantation? long-term outcome of a prospective double blind, placebo-controlled randomized investigator driven study. Liver Transplantation 2013;19:S90.
23. Llado L, Baliellas C, Fabregat J, Ramos E, Torras J, Serrano T, et al. Influence of immunosuppression without steroids in long-term evolution of HCV-recurrence after liver transplantation: results of a prospective randomized study. Liver Transplantation 2011;17(6):S86.
24. Llado L, Fabregat J, Castellote J, Ramos E, Xiol X, Torras J, et al. Immunosuppression without steroids after liver transplantation in HCV-infected patients: results and histological evolution from a prospective randomized study. Liver Transplantation 2008;14(7):S103-4.
25. Llado L, Figueras J, Memba R, Xiol X, Garcia-Gil A, Gonzalez-Pinto N, et al. Immunosuppression without steroids in liver transplantation reduces infectious and metabolic complications but increases rejection rates in non-HCV patients. Liver Transplantation 2005;11(7):C16.
26. Lladó L, Fabregat J, Castellote J, Ramos E, Xiol X, Torras J, et al. Impact of immunosuppression without steroids on rejection and hepatitis C virus evolution after liver transplantation: results of a prospective randomized study. Liver Transplantation 2008;14(12):1752-60.
27. Lladó L, Xiol X, Figueras J, Ramos E, Memba R, Serrano T, et al. Erratum - Immunosuppression without steroids in liver transplantation is safe and reduces infection and metabolic complications: results from a prospective multicenter randomized study (vol 44, pg 710, 2006). Journal of Hepatology 2006;45(1):166.
28. Lladó L, Xiol X, Figueras J, Ramos E, Memba R, Serrano T, et al. Immunosuppression without steroids in liver transplantation is safe and reduces infection and metabolic complications: results from a prospective multicenter randomized study. Journal of Hepatology 2006;44(4):710-6. [DOI: 10.1016/j.jhep.2005.12.010]
29. Xiol X, Castelloote J, Vazquez S, Llado L, Figueras J, Lama C. Prospective randomized trial on the safety and efficacy of steroid free immunosuppression after liver transplantation. Preliminary results [abstract]. Journal of Hepatology 2003;38(Suppl 2):51.
30. Bilbao I, Lazaro JL, Escartin A, Bergamini S, Margarit C. Potential beneficial effect of steroid-free immunosuppression with tacrolimus, after liver transplantation for hepatitis C viral cirrhosis. Liver Transplantation 2004;10(6):C74.
31. Bilbao I, Pou L, Castells L, Charco R, Murio E, Hidalgo E, et al. Tacrolimus in monotherapy in liver transplantation comparison with dual regimen of tacrolimus with steroids. Hepatology 2000;32(4 Pt 2):598A.
32. Bilbao I, Pou L, Lazaro JL, Castells L, Charco R, Murio E. Tacrolimus in monotherapy in liver transplant. Comparison with a dual regimen of tacrolimus with steroids [abstract]. Journal of Hepatology 2001;34(1):61-2.
33. Charco R, Bilbao I, Chavez R, Castells LI, Hidalgo E, Margarit C. Low incidence of hypercholesterolemia among liver transplant patients under tacrolimus monotherapy immunosuppression. Transplantation Proceedings 2002;34(5):1555-6.
34. Margarit C, Bilbao I, Castells L, Lopez I, Pou L, Allende E, et al. A prospective randomized trial comparing tacrolimus and steroids with tacrolimus monotherapy in liver transplantation: the impact on recurrence of hepatitis C. Transplantation International 2005;18(12):1336-45. [DOI: 10.1111/j.1432-2277.2005.00217.x]
35. Everson GT. Is early steroid withdrawal after liver transplantation feasible with tacrolimus monotherapy. Nature Clinical Practice Gastroenterology and Hepatology 2008;5(4):194-5.
36. Moench C, Barreiros AP, Schuchmann M, Bittinger F, Thiesen J, Hommel G, et al. Tacrolimus monotherapy without steroids after liver transplantation--a prospective randomized double-blinded placebo-controlled trial. American Journal of Transplantation 2007;7(6):1616-23.
37. Moench C, Grebe A, Schuchmann M, Otto G. FK506 monotherapy early steroid reduction for liver transplant recipients - a prospective randomised double blinded placebo controlled trial [abstract]. Liver Transplantation 2005;11(7):C25.
38. Moench C, Grebe A, Schunchmann M, Bittinger F, Lohse AW, Otto G. FK506 monotherapy after early steroid reduction for liver transplant recipients - prospective randomised double blinded placebo controlled trial [abstract]. 3rd International Congress on Immunosuppression. San Diego, 2004.
39. Moench C, Schuchmann M, Bittinger F, Otto G. FK506 monotherapy after early steroid withdrawal for liver transplant recipients - a prospective randomised double blinded placebo controlled trial [abstract]. Transplantation 2006;82:230.
40. Moench C, Schuchmann M, Otto G. Remodeling of glucose after liver transplantation under steroid freedom - results of a prospective randomised placebo-controlled double-blind study. Zeitschrift für Gastroenterologie 2007;45(1):119.
41. Weiler N, Thrun I, Hoppe-Lotichius M, Zimmermann T, Kraemer I, Otto G. Early steroid-free immunosuppression with FK506 after liver transplantation: long-term results of a prospectively randomized double-blinded trial. Transplantation 2010;90(12):1562-6.
42. Pageaux G, Boillot O, Calmus Y, Ducerf C, Vanlemmens C, Boudjema K, et al. Early steroid withdrawal after liver transplantation: a placebo controlled study. Hepatology 2003;38(4):370A.
43. Pageaux GP, Calmus Y, Boillot O, Ducerf C, Vanlemmens C, Boudjema K, et al. Steroid withdrawal at day 14 after liver transplantation: a double-blind, placebo-controlled study. Liver Transplantation 2004;10(12):1454-60.
44. Magar A, Pelletier SJ, Englesbe MJ, Welling TH, Al-Holou WN, Fontana RJ, et al. Randomized prospective study suggesting worse outcomes for complete steroid avoidance in liver transplantation. Hepatology 2006;44(4):405A.
45. Pelletier SJ, Ammori JB, Englesbe MJ, Sung RS, Magee JC, Fontana RJ. A prospective, randomized trial of complete steroid avoidance in liver transplantation. Liver Transplantation 2008;14(7 Suppl 1):S224.
46. Pelletier SJ, Debroy MA, Sung RS, Magee JC, Merion RM, Campbell DA, et al. Randomized prospective study of complete steroid avoidance in liver transplantation. Liver Transplantation 2004;10(6):C74.
47. Pelletier SJ, Debroy MA, Vanderwall K, Sung RS, Magee JC, Campbell DA, et al. Analysis of early outcomes of a prospective, randomized trial of complete steroid avoidance in liver transplantation. Transplantation 2004;78(2):378.
48. Pelletier SJ, Englesbe MJ, Vanderwall K, Sung RS, Magee JC, Merion RM, et al. Complete steroid avoidance in a randomized controlled trial is not associated with a decreased incidence of hepatitis C virus recurrence following liver transplantation [abstract]. 3rd International Congress on Immunosuppression. San Diego, 2004.
49. Pelletier SJ, Nadig SN, Lee DD, Ammori JB, Englesbe MJ, Sung RS, et al. A prospective, randomized trial of complete avoidance of steroids in liver transplantation with follow-up of over 7 years. HPB: the Official Journal of the International Hepato Pancreato Biliary Association 2013;15(4):286-93.
50. Pelletier SJ, Vanderwall K, Debroy MA, Englesbe MJ, Sung RS, Magee JC, et al. Preliminary analysis of early outcomes of a prospective, randomized trial of complete steroid avoidance in liver transplantation. Transplantation Proceedings 2005;37(2):1214-6.
51. Doria C, Ramirez CB, Frank A, Navarro V, Herrine S, Rossi S, et al. Complete corticosteroid (CS)-avoidance immunosuppression (is) regimen with basiliximab (BSX) induction and tacrolimus (TAC) in adult liver transplantation (OLT) [abstract no: 1247]. Transplantation 2008;86(2S):423.
52. Doria C, Ramirez CB, Frank A, Navarro V, Herrine S, Rossi S, et al. Safety and efficacy of enteric coated mycophenolate sodium (EC-MPS) in combination with basiliximab (BSX) induction, tacrolimus (TAC) with or without corticosteroids (CS) in adult liver transplantation (OLT) [abstract no: 1246]. Transplantation 2008;86(2S):423.
53. Ramirez CB, Doria C, Frank A, Navarro V, Herrine S, Rossi S, et al. Complete corticosteroid (CS)-avoidance with basiliximab (BSX) induction, tacrolimus (TAC) and enteric coated mycophenolate sodium (EC-MPS) is safe and effective in adult liver transplantation: preliminary results [abstract no: P166]. Transplantation International 2007;20(Suppl 2):135.
54. Ramirez CB, Doria C, Frank A, Navarro V, Herrine S, Rossi S, et al. Safety and efficacy of enteric coated mycophenolate sodium (EC-MPS) in conjunction with basiliximab (BSX) induction, tacrolimus (Tac) with or without corticosteroids (CS) in adult liver transplantation [abstract no: P164]. Transplantation International 2007;20(Suppl 2):135.
55. Ramirez CB, Doria C, Frank AM, Armenti ST, Marino IR. Completely steroid-free immunosuppression in liver transplantation: a randomized study. Clinical Transplantation 2013;27(3):463-71.
56. Ramirez CB, Doria C, Frank AM, Navarro V, Herrine S, Rossi S. Safety and efficacy of steroid-free immunosuppression using basiliximab induction, tacrolimus and enteric coated mycophenolate sodium in adult liver transplantation. Liver Transplantation 2008;14(7 Suppl 1):S109.
57. Reggiani P, Arru M, Regazzi M, Gatti S, Molinaro MD, Caccamo L, et al. A "steroid-free" tacrolimus and low-dose mycophenolate mofetil primary immunosuppression does not prevent early acute rejection after liver transplantation. Transplantation Proceedings 2005;37(4):1697-9.
58. Reggiani P, Regazzi M, Arru M, Gatti S, Rossi G, Molinaro MD, et al. A "steroid-free" tacrolimus and low-dose mycophenolate mofetil primary immunosuppression does not prevent early acute rejection after liver transplantation [abstract]. 3rd International Congress on Immunosuppression. San Diego, 2004.
59. Studenik P, Mejzlik V, Stouracova M, Ondrasek J, Cerny J. Steroid free tacrolimus and mycophenolate mofetil based immunosuppression in liver transplant recipients. Open label, randomised, prospective study [abstract]. Liver Transplantation 2005;11(7):C42.
60. Tisone G, Angelico M, Palmieri G, Pisani F, Anselmo A, Baiocchi L, et al. A pilot study on the safety and effectiveness of immunosuppression without prednisone after liver transplantation. Transplantation 1999;67(10):1308-13.
61. Tisone G, Angelico M, Palmieri G, Pisani F, Baiocchi L, Anselmo A, et al. Prednisone is unnecessary as routine treatment after liver transplantation (OLT) [abstract]. Journal of Hepatology 1998;28(1 Suppl 1):53.
62. Tisone G, Angelico M, Palmieri G, Pisani F, Baiocchi L, Vennarecci G, et al. Immunosuppression without prednisone after liver transplantation is safe and associated with normal early graft function: preliminary results of a randomized study. Transplantation International 1998;11(Suppl 1):S267-9.
63. Tisone G, Angelico M, Vennarecci G, Palmieri G, Buonomo O, Negrini S, et al. Metabolic findings after liver transplantation within a randomised trial with or without steroids. Transplantation Proceedings 1998;30(4):1447-8.
64. Tisone G, Anselmo A, Tariciotti L, Monaco A, Daniele S, De Luca L, et al. Long-term results of a randomized trial on immunosuppression with or without steroids after liver transplantation [abstract no: P148]. Transplantation International 2007;20(Suppl 2):131.
65. Tisone G, Tariciotti L, Daniele S, Monaco A, De Luca L, Manuelli M, et al. Long-term results of a randomized trial on immunosuppression with or without steroids after liver transplantation in human. American Journal of Transplantation 2007;7(Suppl 2):Abstract No. 1274.
66. Vivarelli M, Burra P, Barba G, Canova D, Senzolo M, Cucchetti A. Effect of different steroid schedules on HCV recurrence after liver transplantation: results of the Epaster trial. Liver Transplantation 2008;14(7 Suppl 1):S178.
67. Vivarelli M, Burra P, La Barba G, Canova D, Senzolo M, Cucchetti A, et al. Influence of steroids on HCV recurrence after liver transplantation: a prospective study. Journal of Hepatology 2007;47(6):793-8.
68. Benitez CE, Puig-Pey I, Lopez M, Martinez-Llordella M, Lozano JJ, Bohne F, et al. ATG-fresenius treatment and low-dose tacrolimus: results of a randomized controlled trial in liver transplantation. American Journal of Transplantation 2010;10(10):2296-304.
69. Boillot O, Mayer D, Boudjema K. Effective and safe steroid-free immunosuppression with a tacrolimus/daclizumab regimen after liver transplantation [abstract]. American Journal of Transplantation 2003;3:324.
70. Boillot O, Mayer DA, Boudjema K, Salizzoni M, Gridelli B, Filipponi F, et al. Corticosteroid-free immunosuppression with tacrolimus following induction with daclizumab: a large randomized clinical study. Liver Transplantation 2005;11(1):61-7.
71. Cosimi AB, Cho SI, Delmonico FL, Kaplan MM, Rohrer RJ, Jenkins RL. A randomized clinical trial comparing OKT3 and steroids for treatment of hepatic allograft rejection. Transplantation 1987;43(1):91-5.
72. Cuervas-Mons V, Herrero JI, Gomez MA, Gonzalez I, Serrano T, de la Mata M, et al. Impact of an steroid-free immunosuppression regimen (tacrolimus+mycophenolate mofetil) versus a conventional regimen (tacrolimus+steroids) in cardiovascular risk factors after liver transplantation: preliminary results [abstract no: 477]. American Journal of Transplantation 2009;9(Suppl 2):329.
73. Day CP, O'Grady J, Mayer D, Simpson K, Millson CE, Solomons N, et al. A randomised controlled trial of calcineurin inhibitor (CNI) replacement with mycophenolate mofetil and steroids in liver transplant patients with renal dysfunction. Hepatology 2004;40(4 Suppl 1):547A.
74. De Simone P, De Carlis L, Filipponi F, Grazi GL, Cuomo O, Santaniello W, et al. Results of a multicenter, randomized, open-label, controlled clinical trial comparing basiliximab versus steroids in hepatitis C positive liver transplant patients. Transplantation International 2007;20:33.
75. De Simone P, De Carlis L, Grazi GL, Cuomo O, Calise F, Castagneto M, et al. Results of a multicenter, randomized, open-label trial comparing basiliximab vs. steroids in HCV liver transplant patients. American Journal of Transplantation 2007;7:312.
76. Filipponi F, Callea F, Salizzoni M, Grazi GL, Fassati LR, Rossi M, et al. Double-blind comparison of hepatitis C histological recurrence rate in HCV+ Liver transplant recipients given basiliximab + steroids or basiliximab + placebo, in addition to cyclosporine and azathioprine. Transplantation 2004;78(10):1488-95.
77. Foroncewicz B, Mucha K, Ryszkowska E, Ciszek M, Ziolkowski J, Porowski D, et al. Safety and efficacy of steroid-free immunosuppression with tacrolimus and daclizumab in liver transplant recipients: 6-year follow-up in a single center. Transplantation Proceedings 2009;41(8):3103-6.
78. Ganschow R, Melter M, Wallot M, Schulz A, Pfister E, Baumann U, et al. Maintained efficacy with steroid minimization after pediatric liver transplantation with basiliximab (Simulect (R)) induction therapy: a multicenter randomized 12-month trial. Pediatric Transplantation 2005;9:87.
79. Ganschow R, Melter M, Wallot M, Schulz A, Pfister E, Baumann U, et al. Maintained efficacy with steroid minimization after pediatric liver transplantation with basiliximab (Simulect) induction therapy: a multicenter randomized 12-month trial. Clinical Immunology 2006;119:S37-8.
80. Ganschow R, Melter M, Wallot M, Schulz A, Pfister ED, Baumann U, et al. Maintained efficacy with steroid minimization after pediatric liver transplantation with basiliximab (Simulect) induction therapy: a multicenter randomized 12-month trial [abstract]. Liver Transplantation 2005;11(7):C20.
81. Ganschow R, Melter M, Wallot M, Schulz A, Pfister ED, Baumann U, et al. Maintained efficacy with steroid minimization in pediatric liver transplant recipients with basiliximab (Simulect) induction therapy: a German multicenter randomized 12-month trial. Pediatric Transplantation 2007;11:36.
82. Jonas S, Guckelberger O, Tullius SG, Steinmuller T, Muller AR, Grauhan O, et al. Corticosteroid-free therapy after tacrolimus-based dual immunosuppression versus cyclosporine-based quadruple-induction therapy. Transplantation Proceedings 2001;33(3):2232-3.
83. Junge G, Neuhaus R, Schewior L, Klupp J, Guckelberger O, Langrehr JM, et al. Withdrawal of steroids: a randomized prospective study of prednisone and tacrolimus versus mycophenolate mofetil and tacrolimus in liver transplant recipients with autoimmune hepatitis. Transplantation Proceedings 2005;37(4):1695-6.
84. Junge G, Neuhaus R, Schewior LV, Klupp J, Langrehr JM, Tullius S, et al. Withdrawal of steroids: a randomized prospective study of prednisone and tacrolimus versus mycophenolate mofetil and tacrolimus in liver transplant recipients with autoimmune hepatitis [abstract]. 3rd International Congress on Immunosuppression. San Diego, 2004.
85. Langrehr JM, Neumann UP, Lang M, Muller AR, Jonas S, Settmacher U, et al. First results from a prospective randomized trial comparing steroid-free induction therapy with tacrolimus and MMF versus tacrolimus and steroids in patients after liver transplantation for HCV. Transplantation Proceedings 2002;34(5):1565-6.
86. Mogl MT, Neumann UP, Bahra M, Langrehr JM, Klupp J, Neuhaus P. A prospective randomized trial comparing tacrolimus and mycophenolate mofetil versus tacrolimus and steroids as immunosuppressive induction therapy in hepatitis C positive patients after OLT [abstract]. 3rd International Congress on Immunosuppression. San Diego, 2004.
87. Mogl MT, Neumann UP, Langrehr JM, Neuhaus P. A prospective randomized trial comparing steroid-free immunosuppression induction with tacrolimus and MMF versus tacrolimus and steroids in patients with HCV. American Journal of Transplantation 2004;4(Suppl 8):364.
88. Kato T, Gaynor JJ, Yoshida H, Montalvano M, Takahashi H, Pyrsopoulos N, et al. Randomized trial of steroid-free induction versus corticosteroid maintenance among orthotopic liver transplant recipients with hepatitis C virus: impact on hepatic fibrosis progression at one year. Transplantation 2007;84(7):829-35.
89. Kato T, NeffG, Montalbano M, Hung OM, Lavandera R, Weppler D, et al. Steroid-free induction with tacrolimus and daclizumab in liver transplant recipients with hepatitis C - a preliminary report of a prospective randomized trial. American Journal of Transplantation 2001;1(Suppl 1):179.
90. Kato T, NeffGW, Montalbano M, Hung O, Lavandera R, Levi D, et al. Steroid-free induction with daclizumab and tacrolimus in liver transplant recipients with Hepatitis C - a preliminary report [abstract]. Hepatology 2001;34(4):362A.
91. Kato T, Yoshida H, Gaynor J, Martinez E, Nishida S, Moon J. Impact of steroid-free induction, MMF and pre-emptive antiviral therapy for liver transplant recipients with hepatitis C [abstract no: 1446]. American Journal of Transplantation 2005;5(Suppl 11):524.
92. Kato T, Yoshida H, Hung O, Montalbano M, NeffG, Sadfar K, et al. Steroid free immunosuppression for liver transplantation recipients with hepatitis C - a prospective randomized study. Gastroenterology 2004;126(4):A699.
93. Kato T, Yoshida H, Hung O, Montalvano M, NeffG, Sadfar K, et al. Steroid free induction for liver transplant recipients with hepatitis C - a prospective randomized study. American Journal of Transplantation 2004;4(Suppl 8):504.
94. Kato T, Yoshida H, Sadfar K, Martinez E, Madariaga J, Nishida S. Steroid free induction and pre-emptive antiviral therapy for liver transplant recipients with hepatitis C - prospective randomized study. Transplantation 2004;78(2):379.
95. Kato T, Yoshida H, Sadfar K, Martinez E, Nishida S, Moon J, et al. Steroid-free induction and preemptive antiviral therapy for liver transplant recipients with hepatitis C: a preliminary report from a prospective randomized study. Transplantation Proceedings 2005;37(2):1217-9.
96. Fasola C, Heffron T, Sher L, Douglas D, Brown R, Ham J, et al. Multicenter randomized hepatitis C (HCV) three trial post liver transplantation (OLT): a one-year follow up. American Journal of Transplantation 2005;5:276.
97. Fasola C, Klintmalm G, Hepatitis C Three Group. Multicenter randomized hepatitis C-three trial post liver transplantation: one-year interim report. Liver Transplantation 2006;12(5):C115.
98. Fasola CG, Heffron TG, Sher L, Douglas DD, Brown R, Ham J, et al. Multicenter randomized hepatitis C (HCV) three trial post liver transplantation (OLT): a 90-day report. Hepatology 2004;40(4 Suppl 1):163A.
99. Klintmalm G, Fasola CG, Jennings L, Heffron TG, Sher LS, Mulligan DC, et al. Hepatitis C (HCv)-3 study: severe HCV recurrence post liver transplantation (OLT) is decreased in patients treated with mycophenolate mofetil, particularly, in the absence of steroids. Hepatology 2008;48(Suppl 4):338A.
100. Klintmalm G, Fasola CG, Jennings LW. Hepatitis C (HCV)-3 study: day-90 protocol biopsy (PB) grade is a surrogate marker for severe HCV recurrence (R), onPB, at years 1 and 2 post liver transplantation (OLT). Hepatology 2009;50(4 Suppl):1028A.
101. Klintmalm GB, Davis GL, Teperman L, Netto GJ, Washburn K, Rudich SM, et al. A randomized, multicenter study comparing steroid-free immunosuppression and standard immunosuppression for liver transplant recipients with chronic hepatitis C. Liver Transplantation 2011;17(12):1394-403.
102. Klintmalm GB, Fasola CG, Jennings L. Hepatitis C (HCV)-3 study: decreased incidence of severe HCV recurrence (R) post liver transplantation (OLT) in patients (Pt) treated with mycophenolate mofetil (MMF), particularly, in the absence of steroids (Pred) [abstract no: 52]. American Journal of Transplantation 2009;9(Suppl 2):206.
103. Klintmalm GB, Fasola CG, Jennings L, Heffron TG, Sher L, Mulligan D. Hepatitis C (HCV)-3 study: benefits of a steroid-free immunosuppression (is) regimen in HCV-infected liver transplant recipients (OLT) may become evident only after long-term follow up. Liver Transplantation 2008;14(7 Suppl 1):S105.
104. Klintmalm GB, Washburn WK, Rudich SM, Heffron TG, Teperman LW, Fasola C, et al. Corticosteroid-free immunosuppression with daclizumab in HCV(+) liver transplant recipients: 1-year interim results of the HCV-3 study. Liver Transplantation 2007;13(11):1521-31.
105. Lupo L, Panzera P, Tandoi F, Carbotta G, Giannelli G, Santantonio T, et al. Basiliximab versus steroids in double therapy immunosuppression in liver transplantation: a prospective randomized clinical trial. Liver Transplantation 2008;86(7):925-31.
106. Lupo L, Ricci P, Caputi L, Tandoi F, Aquilino F, Di Palma G, et al. Basiliximab vs steroids in liver transplantation immunosuppression. A prospective randomized clinical trial. Liver Transplantation 2005;11(7):C75.
107. Cholongitas E, Samonakis D, Manousou P, Shusang V, Dhillon A, Quaglia A, et al. Randomised trial of tacrolimus monotherapy vs. tacrolimus/azathioprine/prednisolone after liver transplantation for HCV cirrhosis. Liver Transplantation 2006;12(5):C61.
108. Manousou P, Samonakis D, Cholongitas E, Patch D, O'Beirne J, Dhillon AP, et al. Outcome of recurrent hepatitis C virus after liver transplantation in a randomized trial of tacrolimus monotherapy versus triple therapy. Liver Transplantation 2009;15(12):1783-91.
109. Manousou P, Samonakis D, Corbani A, Cholongitas E, Sigalas A, Xirouchakis E, et al. Long term results of a randomized trial of tacrolimus monotherapy versus triple therapy in HCV cirrhosis liver transplant recipients. Hepatology 2007;46(4):484A.
110. Manousou P, Samonakis D, Tsochatzis E, Cholongitas E, Davidson J, Patch D, et al. Long term-8 year follow up of a randomized trial of tacrolimus monotherapy versus triple therapy after liver transplantation for HCV cirrhosis. Journal of Hepatology 2013;58:S11.
111. Samonakis DN, Cholongitas E, Triantos CK, Quaglia A, Senzolo M, Dhillon AP, et al. Randomised trial of tacrolimus monotherapy vs. tacrolimus/azathioprine/prednisolone after liver transplantation for HCV cirrhosis: preliminary results. Journal of Hepatology 2005;42(Suppl 2):47.
112. Samonakis DN, Mela M, Quaglia A, Triantos CK, Thalheimer U, Leandro G, et al. Rejection rates in a randomised trial of tacrolimus monotherapy versus triple therapy in liver transplant recipients with hepatitis C virus cirrhosis. Transplant Infectious Disease 2006;8(1):3-12.
113. McDiarmid SV, Farmer DA, Goldstein LI, Martin P, Vargas J, Tipton JR, et al. A randomized prospective trial of steroid withdrawal after liver transplantation. Transplantation 1995;60(12):1443-50.
114. Eason JD, Blazek J, Mason A, Loss GE. Steroid-free immunosuppression through thymoglobulin induction in liver transplantation: results of a prospective randomized trial [abstract]. Hepatology 2000;32(4):208A.
115. Eason JD, Loss GE, Blazek J, Nair S, Mason AL. Steroid-free liver transplantation using rabbit antithymocyte globulin induction: results of a prospective randomized trial. Liver Transplantation 2001;7(8):693-7.
116. Eason JD, Nair S, Cohen AJ, Blazek JL, Loss GE Jr. Steroid-free liver transplantation using rabbit antithymocyte globulin and early tacrolimus monotherapy. Transplantation 2003;75(8):1396-9.
117. Nair S, Loss G, Cohen A, Eason J. Severity of recurrent hepatitis C infection after liver transplant: a comparative study between steroid induction vs induction with rabbit anti thymocyte globulin: results of a randomized controlled study. Hepatology 2004;40(4 Suppl 1):241A.
118. Nair S, Loss GE, Cohen AJ, Eason JD. Induction with rabbit antithymocyte globulin versus induction with corticosteroids in liver transplantation: impact on recurrent hepatitis C virus infection. Transplantation 2006;81(4):620-2.
119. Nair S, Lipscomb J, Eason J. Efficacy of interferon based antiviral therapy for recurrent hepatitis C in patients who received steroid free immunosuppression for liver transplantation. Liver Transplantation 2008;86(3):418-22.
120. Neumann U, Samuel D, Trunecka P, Gugenheim J, Gerunda G, Friman S. A randomized multicenter study comparing a tacrolimus-based protocol with and without steroids in HCV-positive liver allograft recipients. Journal of Transplantation 2012;2012:894215.
121. Otero A, Varo E, Ortiz de Urbina J, Martin-Vivaldi R, Cuervas-Mons V, Gonzalez-Pinto I, et al. Steroid-free maintenance regimen versus standard treatment in liver transplant recipients [abstract]. 3rd International Congress on Immunosuppression. San Diego, 2004.
122. Otero A, Varo E, de Urbina JO, Martin-Vivaldi R, Cuervas-Mons V, Gonzalez-Pinto I, et al. A prospective randomized open study in liver transplant recipients: daclizumab, mycophenolate mofetil, and tacrolimus versus tacrolimus and steroids. Liver Transplantation 2009;15(11):1542-52.
123. Saliba F, Durand F, Gugenheim J, Radenne S, Leroy V, Neau-Cransac M, et al. Steroid-free regimen and optimization of mycophenolic acid (MPA) exposure in liver transplant recipients: final results of a randomized multicenter trial. Hepatology 2012;56:515A.
124. Saliba F, Rostaing L, Gugenheim J, Durand F, Radenne S, Neau-Cransac M. Optimisation of mycophenolic acid (MPA) exposure for a steroid-free regimen in liver graft recipients: interim results from the Celleste Study [abstract no: 458]. American Journal of Transplantation 2010;10(Suppl 4):174.
125. Spada M, Bertani A, Colledan M, Sonzogni A, Guizzetti M, Lucianetti A, et al. A randomized trial for tacrolimus and steroids vs. tacrolimus and basiliximab in pediatric liver transplantation. Pediatric Transplantation 2005;9:57.
126. Spada M, Bertani A, Petz W, Torri E, Sonzogni A, Guizzetti M, et al. A randomized trial for tacrolimus and steroids vs tacrolimus and basiliximab in paediatric liver transplantation [abstract]. 3rd International Congress on Immunosuppression. San Diego, 2004.
127. Spada M, Bertani A, Petz W, Torri E, Sonzogni A, Guizzetti M, et al. A randomized trial for tacrolimus and steroids vs. tacrolimus and basiliximab in pediatric liver transplantation. Hepatology 2004;40(4 Suppl 1):473A.
128. Spada M, Petz W, Bertani A, Riva S, Sonzogni A, Giovannelli M, et al. Randomized trial of basiliximab induction versus steroid therapy in pediatric liver allograft recipients under tacrolimus immunosuppression. American Journal of Transplantation 2006;6(8):1913-21.
129. Takada Y, Kaido T, Asonuma K, Sakurai H, Kubo S, Kiuchi T, et al. Randomized trial comparing tacrolimus and steroid with tacrolimus and mycophenolate mofetil among HCV-positive recipients of living donor liver transplantation. Liver Transplantation 2012;18:S227.
130. Takada Y, Kaido T, Asonuma K, Sakurai H, Kubo S, Kiuchi T, et al. Randomized, multicenter trial comparing tacrolimus plus mycophenolate mofetil to tacrolimus plus steroids in hepatitis C virus-positive recipients of living donor liver transplantation. Liver Transplantation 2013;19(8):896-906.
131. Teisseyre J, Kalicinski P, Markiewicz M, Szymczak M, Ismail H, Pawlowska J, et al. A comparison of two methods of tacrolimus based immunosuppression with or without MMF for early steroid withdrawal in children after liver transplantation - preliminary results. Liver Transplantation 2006;12(5):C71.
132. Turner S, Dhamarajah S, Bosomworth M, Bellamy M, Leeds Liver Transplant Group. Effect of perioperative steroids on renal function after liver transplantation. Anaesthesia 2006;61(3):253-9.
133. Jensen A, Maxwell P. Six-year follow-up of "steroid elimination 24 hours after liver transplantation using daclizumab, tacrolimus, and mycophenolate mofetil" [abstract]. American Journal of Transplantation 2006;6:210.
134. Washburn K, Speeg K, Esterl R. Liver transplantation using minimal steroids, prograf, cellcept and daclizumab [abstract]. Transplantation 2000;69:S166.
135. Washburn K, Speeg KV, Esterl R, Cigarroa F, Pollack M, Tourtellot C, et al. Steroid elimination 24 hours after liver transplantation using daclizumab, tacrolimus, and mycophenolate mofetil. Transplantation 2001;72(10):1675-9.
136. Zhong L, Peng Z, Liu J, Peng G, Wang C. Liver transplantation results in hepatocellular carcinoma patients with immunosuppression without steroids from a prospective multicenter randomized study in China. Liver Transplantation 2010;16(6):S184.
137. Adams RW, Chapman RL, Smallwood GA. Steroid withdrawal in liver transplant recipients. Progress in Transplantation 2001;11(3):217-23. [1526-9248]
138. Allison AC, Eugui EM. Mycophenolate mofetil and its mechanisms of action. Immunopharmacology 2000;47(2-3):85-118.
139. Brok J, Thorlund K, Gluud C, Wetterslev J. Trial sequential analysis reveals insufficient information size and potentially false positive results in many meta-analyses. Journal of Clinical Epidemiology 2008;61:763-9.
140. Brok J, Thorlund K, Wetterslev J, Gluud C. Apparently conclusive meta-analyses may be inconclusive - trial sequential analysis adjustment of random error risk due to repetitive testing of accumulating data in apparently conclusive neonatal meta-analyses. International Journal of Epidemiology 2009;38(1):287-98.
141. Cintorino D, Riva S, Spada M, Minervini M, Sonzogni A, Scotti Foglieni C, et al. Corticosteroid-free immunosuppression in pediatric liver transplantation: safety and efficacy after a short-term follow-up. Transplantation Proceedings 2006;38(4):1099-100. [0041-1345]
142. DeMets DL. Methods for combining randomized clinical trials: strengths and limitations. Statistics in Medicine 1987;6(3):341-50.
143. DerSimonian R, Laird N. Meta-analysis in clinical trials. Controlled Clinical Trials 1986;7(3):177-88.
144. Dienstag JL, Cosimi AB. Liver transplantation - a vision realized. New England Journal of Medicine 2012;367(16):1483-5.
145. Egger M, Davey Smith G, Schneider M, Minder C. Bias in meta-analysis detected by a simple, graphical test. BMJ (Clinical Research Ed.) 1997;315(7109):629-34.
146. Esmore DS, Spratt PM, Keogh AM, Chang VP. Cyclosporine and azathioprine immunosuppression without maintenance steroids: a prospective randomized trial. Journal of Heart Transplantation 1989;8(3):194-9.
147. Eurotransplant. Annual Report 2012. www.eurotransplant.org/cms/mediaobject.php?file=AR2012.pdf (accessed 25 March 2014).
148. Fernandez-Miranda C, Guijarro C, de la Calle A, Loinaz C, Gonzalez-Pinto I, Gomez-Izquierdo T, et al. Lipid abnormalities in stable liver transplant recipients-effects of cyclosporin, tacrolimus, and steroids. Transplant International 1998;11(2):137-42. [0934-0874]
149. Ganschow R, Grabhorn E, Schulz A, Von Hugo A, Rogiers X, Burdelski M. Long-term results of basiliximab induction immunosuppression in pediatric liver transplant recipients. Pediatric Transplantation 2005;9(6):741-5. [1397-3142]
150. Gluud C, Nikolova D, Klingenberg SL. Cochrane Hepato-Biliary Group. About Cochrane (Cochrane Review Groups (CRGs)) 2015, Issue 7. Art. No.: LIVER.
151. Brozek J, Oxman A, Schünemann H. GRADEpro. Version 3.2 for Windows. Grade Working Group 2004-2007, 2008.
152. Gruessner RW, Sutherland DE, Parr E, Humar A, Gruessner AC. A prospective, randomized, open-label study of steroid withdrawal in pancreas transplantation-a preliminary report with 6-month follow-up. Transplantation Proceedings 2001;33(1-2):1663-4.
153. Gu J, Wu X, Lu L, Zhang S, Bai J, Wang J, et al. Role of steroid minimization in the tacrolimus-based immunosuppressive regimen for liver transplant recipients: a systematic review and meta-analysis of prospective randomized controlled trials. Hepatology International 2014;8:198-215.
154. Haddad EM, McAlister VC, Renouf E, Malthaner R, Kjaer MS, Gluud LL. Cyclosporin versus tacrolimus for liver transplanted patients. Cochrane Database of Systematic Reviews 2006, Issue 4. [DOI: 10.1002/14651858.CD005161.pub2]
155. Hatz HJ. Glucocorticosteroids: immunological basis, pharmacology and therapeutic guidelines [Glucocorticoide: immunologische Grundlagen, Pharmakologie und Therapierichtlinien]. Medizinisch-Pharmakologisches Kompendium. Vol. 12, Stuttgart: Wissenschaftliche Verlagsgesellschaft, 1998:514. [3804714862]
156. Higgins JPT, Thompson SG. Quantifying heterogeneity in a meta-analysis. Statistics in Medicine 2002;21(11):1539-58.
157. Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. Available from www.cochrane-handbook.org.
158. Hirose R, Vincenti F. Immunosuppression: today, tomorrow, and withdrawal. Seminars in Liver Disease 2006;26(3):201-10. [0272-8087]
159. Ho S, Clipstone N, Timmermann L, Northrop J, Graef I, Fiorentino D, et al. The mechanism of action of cyclosporin A and FK506. Clinical Immunology and Immunopathology 1996;80(3):S40-5.
160. International Conference on Harmonisation Expert Working Group. International conference on harmonisation of technical requirements for registration of pharmaceuticals for human use. ICH harmonised tripartite guideline. Guideline for good clinical practice CFR & ICH Guidelines. Vol. 1, Pennsylvania: Barnett International/PAREXEL, 1997.
161. An International Panel. Update of the international BanffSchema for liver allograft rejection: working recommendations for the histopathologic staging and reporting of chronic rejection. Hepatology 2000;31:792.
162. International Working Party. Terminology for hepatic allograft rejection. Hepatology 1995;22:648.
163. Johnson RJ, Bradbury LL, Martin K, Neuberger J. Organ donation and transplantation in the UK-the last decade: a report from the UK national transplant registry. Transplantation 2014;97(Suppl 1):S1-27.
164. Kato T, Yoshida H, Sadfar K, Martinez E, Nishida S, Moon J, et al. Steroid-free induction and preemptive antiviral therapy for liver transplant recipients with hepatitis C: a preliminary report from a prospective randomized study. Transplantation Proceedings 2005;37(2):1217-9. [0041-1345]
165. Keus F, Wetterslev J, Gluud C, Gooszen HG, van Laarhoven CJ. Robustness assessments are needed to reduce bias in meta-analyses that include zero-event randomized trials. American Journal of Gastroenterology 2009;104:546-51.
166. Kjaergard LL, Villumsen J, Gluud C. Reported methodologic quality and discrepancies between large and small randomized trials in meta-analyses. Annals of Internal Medicine 2001;135(11):982-9.
167. Knight SR, Russell NK, Barcena L, Morris PJ. Mycophenolate mofetil decreases acute rejection and may improve graft survival in renal transplant recipients when compared with azathioprine: a systematic review. Transplantation 2009;87(6):785-94.
168. Knight SR, Morris PJ. Steroid avoidance or withdrawal after renal transplantation increases the risk of acute rejection but decreases cardiovascular risk. A meta-analysis. Transplantation 2010;89(1):1-14.
169. Knight SR, Morris PJ. Steroid sparing protocols following nonrenal transplants; the evidence is not there. A systematic review and meta-analysis. Transplant International 2011;24(12):1198-207.
170. Lundh A, Sismondo S, Lexchin J, Busuioc OA, Bero L. Industry sponsorship and research outcome. Cochrane Database of Systematic Reviews 2012, Issue 12. [DOI: 10.1002/14651858.MR000033.pub2]
171. Macaskill P, Walter SD, Irwig L. A comparison of methods to detect publication bias in meta-analysis. Statistics in Medicine 2001;20(4):641-54.
172. Moher D, Pham B, Jones A, Cook DJ, Jadad AR, Moher M, et al. Does quality of reports of randomised trials affect estimates of intervention efficacy reported in meta-analyses?. Lancet 1998;352(9128):609-13.
173. Neal DA, Brown MJ, Wilkinson IB, Alexander GJ. Mechanisms of hypertension after liver transplantation. Transplantation 2005;79(8):935-40.
174. NHS Blood and Transplant. Organ Donation and Transplantation Activity Report 2012/2013. http://www.nhsbt.nhs.uk/2013 (accessed 25 March 2014).
175. Ojo AO, Held PJ, Port FK, Wolfe RA, Leichtman AB, Young EW, et al. Chronic renal failure after transplantation of a nonrenal organ. New England Journal of Medicine 2003;349(10):931-40.
176. Organ Procurement and Transplantation Network. Transplants by donor type. optn.transplant.hrsa.gov/latestData/rptData.asp 2014 (accessed 10 November 2015).
177. Pengel L, Morris P. The Transplant Library of randomized controlled trials and systematic reviews. Transplantation 2011;92(6):613-6.
178. Penninga L, Wettergren A, Chan A-W, Steinbrüchel DA, Gluud C. Calcineurin inhibitor minimisation versus continuation of calcineurin inhibitor treatment for liver transplant recipients. Cochrane Database of Systematic Reviews 2012, Issue 3. [DOI: 10.1002/14651858.CD008852.pub2]
179. Penninga L, Wettergren A, Wilson CH, Chan A-W, Steinbrüchel DA, Gluud C. Antibody induction versus placebo, no induction, or another type of antibody induction for liver transplant recipients. Cochrane Database of Systematic Reviews 2014, Issue 6. [DOI: 10.1002/14651858.CD010253.pub2]
180. Penninga L, Wettergren A, Wilson CH, Chan A-W, Steinbrüchel DA, Gluud C. Antibody induction versus corticosteroid induction for liver transplant recipients. Cochrane Database of Systematic Reviews 2014, Issue 5. [DOI: 10.1002/14651858.CD010252.pub2]
181. Perera MT, Mirza DF, Elias E. Liver transplantation: issues for the next 20 years. Journal of Gastroenterology and Hepatology 2009;24(Suppl 3):S124-31.
182. Pillai AA, Levitsky J. Overview of immunosuppression in liver transplantation. World Journal of Gastroenterology 2009;15(34):4225-33.
183. R Core Team. R: A language and environment for statistical computing. R Foundation for Statistical Computing 2013. [http://www. R-project.org/]
184. Renoult E, Buteau C, Lamarre V, Turgeon N, Tapiero B. Infectious risk in pediatric organ transplant recipients: is it increased with the new immunosuppressive agents?. Pediatric Transplantation 2005;9(4):470-9. [1397-3142]
185. The Nordic Cochrane Centre, The Cochrane Collaboration. Review Manager (RevMan). Version 5.3. Copenhagen: The Nordic Cochrane Centre, The Cochrane Collaboration, 2014.
186. Royle P, Milne R. Literature searching for randomized controlled trials used in Cochrane reviews: rapid versus exhaustive searches. International Journal of Technology Assessment in Health Care 2003;19(4):591-603.
187. Savović J, Jones HE, Altman DG, Harris RJ, Jüni P, Pildal J, et al. Influence of reported study design characteristics on intervention effect estimates from randomized, controlled trials. Health Technology Assessment 2012;16(35):1-82.
188. Savović J, Jones HE, Altman DG, Harris RJ, Jüni P, Pildal J, et al. Influence of reported study design characteristics on intervention effect estimates from randomized, controlled trials. Annals of Internal Medicine 2012;157(6):429-38.
189. Schulz KF, Chalmers I, Hayes RJ, Altman DG. Empirical evidence of bias. Dimensions of methodological quality associated with estimates of treatment effects in controlled trials. JAMA 1995;273(5):408-12.
190. Segev DL, Sozio SM, Shin EJ, Nazarian SM, Nathan H, Thuluvath PJ, et al. Steroid avoidance in liver transplantation: meta-analysis and meta-regression of randomized trials. Liver Transplantation 2008;14(4):512-25.
191. Sgourakis G, Radtke A, Fouzas I, Mylona S, Goumas K, Gockel I, et al. Corticosteroid-free immunosuppression in liver transplantation: a meta-analysis and meta-regression of outcomes. Transplant International 2009;22(9):892-905.
192. Sheiner PA, Schwartz ME, Mor E, Schluger LK, Theise N, Kishikawa K, et al. Severe or multiple rejection episodes are associated with early recurrence of hepatitis C after orthotopic liver transplantation. Hepatology 1995;21(1):30-4.
193. Singh N, Gayowski T, Ndimbie OK, Nedjar S, Wagener MM, Yu VL. Recurrent hepatitis C virus hepatitis in liver transplant recipients receiving tacrolimus: association with rejection and increased immunosuppression after transplantation. Surgery 1996;119(4):452-6.
194. Chan A-W, TetzlaffJM, Altman DG, Laupacis A, Gøtzsche PC, Krleža-Jerić K, et al. SPIRIT 2013 Statement: defining standard protocol items for clinical trials. Annals of Internal Medicine 2013;158(3):200-7.
195. Chan A-W, TetzlaffJM, Gøtzsche PC, Altman DG, Mann H, Berlin J, et al. SPIRIT 2013 explanation and elaboration: guidance for protocols or clinical trials. BMJ (Clinical Research Ed.) 2013;346:e7586.
196. Sterneck M, Kaiser GM, Heyne N, Richter N, Rauchfuss F, Pascher A, et al. Everolimus and early calcineurin inhibitor withdrawal: 3-year results from a randomized trial in liver transplantation. American Journal of Transplantation 2014;14(3):701-10.
197. Sweeting MJ, Sutton AJ, Lambert PC. What to add to nothing? Use and avoidance of continuity corrections in meta-analysis of sparse data. Statistics in Medicine 2004;23:1351-75.
198. Thorlund K, Devereaux PJ, Wetterslev J, Guyatt G, Ioannidis JP, Thabane L, et al. Can trial sequential monitoring boundaries reduce spurious inferences from meta-analyses. International Journal of Epidemiology 2009;38(1):276-86.
199. Thorlund K, Anema A, Mills E. Interpreting meta-analysis according to the adequacy of sample size. An example using isoniazid chemoprophylaxis for tuberculosis in purified protein derivative negative HIV-infected individuals. Clinical Epidemiology 2010;2:57-66.
200. Thorlund K, Imberger G, Walsh M, Chu R, Gluud C, Wetterslev J, et al. The number of patients and events required to limit the risk of overestimation of intervention effects in meta-analysis - a simulation study. PLoS One 2011;6(10):e25491.
201. Thorlund K, Engstrøm J, Wetterslev J, Brok J, Imberger G, Gluud C. User manual for Trial Sequential Analysis (TSA). ctu.dk/tsa/files/tsa_manual.pdf 2011 (accessed 10 November 2015).
202. Copenhagen Trial Unit. TSA - Trial Sequential Analysis. Version 0.9 Beta. Copenhagen: Copenhagen Trial Unit, 2011.
203. Vanrenterghem Y. Strategies to reduce or replace steroid dosing. Transplantation Proceedings 1999;31(Suppl 8A):7S-10S. [0041-1345]
204. Wetterslev J, Thorlund K, Brok J, Gluud C. Trial sequential analysis may establish when firm evidence is reached in cumulative meta-analysis. Journal of Clinical Epidemiology 2008;61:64-75.
205. Wetterslev J, Thorlund K, Brok J, Gluud C. Estimating required information size by quantifying diversity in random-effects model meta-analyses. BMC Medical Research Methodology 2009;9:86.
206. Wiesner RH, Demetris AJ, Belle SH, Seaberg EC, Lake JR, Zetterman RK, et al. Acute hepatic allograft rejection: Incidence, risk factors, and impact on outcome. Hepatology 1998;28(3):638-45.
207. Wood L, Egger M, Gluud LL, Schulz KF, Jüni P, Altman GD, et al. Empirical evidence of bias in treatment effect estimates in controlled trials with different interventions and outcomes: meta-epidemiological study. BMJ (Clinical Research Ed.) 2008;336:601-5.
208. Zaydfudim V, Feurer ID, Landman MP, Moore DE, Wright JK, Pinson CW. Reduction in corticosteroids is associated with better health-related quality of life after liver transplantation. Journal of the American College of Surgeons 2012;214(2):164-73.
209. Fairfield C, Penninga L, Powell J, Harrison EM, Wigmore S. Glucocorticosteroid-free versus glucocorticosteroid-containing immunosuppression for liver transplanted patients. Cochrane Database of Systematic Reviews 2014, Issue 7. [DOI: 10.1002/14651858.CD007606.pub2]
210. Langer G, Saal S, Großmann K, Grothues D, Wienke A. Glucocorticosteroids for liver transplanted patients. Cochrane Database of Systematic Reviews 2009, Issue 1. [DOI: 10.1002/14651858.CD007606]